The biopharma industry broke records again in 2021 with the amount of money raised for drug development. After a year of rapid growth, what will 2022 bring for market dynamics and R&D catalysts in biopharma?

The Scrip 100 universe gathers FY 2020 financial performance data and compares the activities of the top 100 biopharma businesses, ranked by pharma sales. 

Pfizer has dropped to number seven in our top pharma rankings after a long reign. AbbVie has risen to number three, growing through merger expansion.

CES 2022 was missing some marquee names due to the latest coronavirus surge, but there was still plenty to take in at the intersection of digital health and consumer tech. In this roundup, In Vivo highlights some standouts, with commentary from company leaders.

Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.

Having divested non-medical imaging a year ago, Olympus Corp is putting its foot to the floor in refocusing on its medical portfolio. It has set global ambitions of strengthening its coverage of unmet needs and of playing a major role in reshaping health care delivery.

The annual J.P. Morgan Health Care Conference has come to a close. In Vivo has summarized some of the key themes to appear from 2022’s meeting of industry leaders, investors and technology creators.

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

What lessons can be learned from the conviction of Theranos founder Elizabeth Holmes, found guilty on four counts of investor fraud in a US court on 4 January?

Exploring the continued controversy around the 340B US federal drug discount program. As the story moves into 2022, key questions remain unanswered.

Big changes are in store on the drug pricing front in Germany. Further reforms could depend on who is appointed health minister.

While US biosimilar approvals have been thin on the ground in 2021 – with products delayed due to the FDA’s inability to conduct certain facility inspections during the COVID-19 pandemic – the market has nevertheless seen several firsts this year, including two interchangeability designations and the first ophthalmic biosimilar approval.

Eight $1bn+ alliances were penned in December. Topping the list was a potential $12.4bn deal between Recursion and Roche (and its Genentech subsidiary) involving the identification and development of small-molecule programs in a gastrointestinal cancer indication and in key areas of neuroscience. Recursion is responsible for creating a certain number of PhenoMaps, which are massive relational databases of biological and chemical perturbation phenotypes. For each of the PhenoMaps requested by Roche, Recursion may be subject to an initiation fee up to $250m for sixteen accepted PhenoMaps. Recursion will receive an up-front payment of $150m and is eligible for additional performance-based research milestones. Roche and Genentech have the option to obtain an exclusive license to initiate up to 40 programs, each of which, if successfully developed and commercialized, could yield more than $300m in development, commercialization, and sales milestones for Recursion.

It is time for In Vivo's 14th annual Deals of the Year contest. We've selected 15 nominees across three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.

In Vivo's Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2021. Data provided by Biomedtracker.